News | October 09, 2024
Jubilant Ingrevia becomes only Indian company to join WEF’s Global Lighthouse Network
WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse
WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Quinidine Sulphate helps manage rare irregular heartbeat conditions
Subscribe To Our Newsletter & Stay Updated
